HGFα/β CRISPR/Cas9 KO Plasmid (m): sc-420849
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HGFα/β CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HGFα/β genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HGFα Antibody (H-10): sc-374422
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HGFα/β CRISPR/Cas9 KO Plasmid (m) | sc-420849 | 20 µg | $397.00 |
Overview
Mouse Hgf encodes hepatocyte growth factor (HGFα/β), a secreted heterodimeric ligand for the MET receptor tyrosine kinase that coordinates epithelial–mesenchymal signaling. HGF–MET activation engages MAPK/ERK, PI3K–AKT, STAT, and Rho GTPase pathways to regulate proliferation, survival, motility, morphogenesis, and tissue repair. In vivo and in vitro, HGF signaling shapes organ development and regeneration and modulates stromal–epithelial crosstalk within the microenvironment. Dysregulated HGF/MET signaling is widely studied in models of fibrosis, inflammation, and cancer progression, including invasion, angiogenic programs, and metastatic dissemination.
HGFα/β CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Hgf gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Hgf together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Hgf open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HGFα/β protein expression.
This CRISPR knockout system enables efficient generation of Hgf-deficient cell models for investigation of HGFα/β signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Hgf exon(s) critical for HGFα/β function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Hgf genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by HGFα/β CRISPR/Cas9 KO Plasmid (m) and HGFα/β CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Hgf locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by HGFα/β HDR Plasmid (m) and HGFα/β HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Hgf homology arms to support homology-directed repair at defined Hgf target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.